Clinigen (PRIVATE.CLINIGEN)

Overall impact
B (77)

Commentary

Clinigen is a strong overall performer. With a 'B' rating of 77.1 for overall impact (91st percentile compared to all companies), Clinigen ranks 39th out of 260 industry peers, behind Assembly Biosciences, Haleon, MedAvail and 35 others, and ahead of Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 218 others. On top material causes for Clinigen's industry (Pharmaceuticals), Clinigen performs well in Child and Maternal Health (80.0 score), Accountable Institutions (92.1), Accountable Institutions (92.1) and 57 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (31.7 score), Equal Pay and Opportunity (33.9), Equal Pay and Opportunity (33.9) and 9 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.CLINIGEN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2008
Employees
1,000
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United Kingdom
Share classes
PRIVATE.CLINIGEN
Description
Manufacturer of pharmaceutical products and services intended to offer quicker access to new and critical medicines. The company operates in a range of areas of global medicine supply including clinical trials, unlicensed medicines and licensed medicines. This enables clients to deliver the right medicine to the right patient at the right time.
Material causes
Ethos considers the following causes material for Clinigen, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.